NO322372B1 - Fremgangsmate for separasjon av et vitamin K-avhengig protein fra ikke-vitamin K-avhengige, medfolgende proteiner fra en proteinholdig losning - Google Patents

Fremgangsmate for separasjon av et vitamin K-avhengig protein fra ikke-vitamin K-avhengige, medfolgende proteiner fra en proteinholdig losning Download PDF

Info

Publication number: NO322372B1
Authority: NO; Norway
Prior art keywords: protein; vitamin; dependent; proteins; buffer
Prior art date: 1994-02-28

Application number

NO19950733A

Other languages

English (en)

Norwegian (no)

Other versions

NO950733L (no

NO950733D0 (no

Inventor

Artur Mitterer

Friedrich Dorner

Bernhard Fischer

Original Assignee

Baxter Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-28

Filing date

1995-02-27

Publication date

2006-09-25

1995-02-27 Application filed by Baxter Ag filed Critical Baxter Ag

1995-02-27 Publication of NO950733D0 publication Critical patent/NO950733D0/no

1995-08-29 Publication of NO950733L publication Critical patent/NO950733L/no

2006-09-25 Publication of NO322372B1 publication Critical patent/NO322372B1/no

Links

102000004169 proteins and genes Human genes 0.000 title claims abstract description 102
108090000623 proteins and genes Proteins 0.000 title claims abstract description 102
238000000034 method Methods 0.000 title claims abstract description 53
230000008569 process Effects 0.000 title claims abstract description 6
108091005605 Vitamin K-dependent proteins Proteins 0.000 title claims description 44
238000000926 separation method Methods 0.000 title claims description 10
239000012460 protein solution Substances 0.000 title claims description 8
229940088594 vitamin Drugs 0.000 title abstract 4
239000011782 vitamin Substances 0.000 title abstract 4
150000001450 anions Chemical class 0.000 claims abstract description 52
230000001419 dependent effect Effects 0.000 claims abstract description 14
238000004587 chromatography analysis Methods 0.000 claims description 22
229910001424 calcium ion Inorganic materials 0.000 claims description 19
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 18
229940096437 Protein S Drugs 0.000 claims description 16
239000000243 solution Substances 0.000 claims description 13
108010066124 Protein S Proteins 0.000 claims description 12
102000029301 Protein S Human genes 0.000 claims description 12
238000010828 elution Methods 0.000 claims description 12
229930003448 Vitamin K Natural products 0.000 claims description 11
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 11
235000019168 vitamin K Nutrition 0.000 claims description 11
239000011712 vitamin K Substances 0.000 claims description 11
150000003721 vitamin K derivatives Chemical class 0.000 claims description 11
229940046010 vitamin k Drugs 0.000 claims description 11
239000003480 eluent Substances 0.000 claims description 5
239000000758 substrate Substances 0.000 claims description 5
101800004937 Protein C Proteins 0.000 claims description 4
102000017975 Protein C Human genes 0.000 claims description 4
101800001700 Saposin-D Proteins 0.000 claims description 4
229960000856 protein c Drugs 0.000 claims description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
239000011575 calcium Substances 0.000 claims description 3
239000001110 calcium chloride Substances 0.000 claims description 3
235000011148 calcium chloride Nutrition 0.000 claims description 3
229910001628 calcium chloride Inorganic materials 0.000 claims description 3
108010025221 plasma protein Z Proteins 0.000 claims description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
229930003231 vitamin Natural products 0.000 abstract 3
235000013343 vitamin Nutrition 0.000 abstract 3
150000003722 vitamin derivatives Chemical class 0.000 abstract 3
235000018102 proteins Nutrition 0.000 description 94
238000000746 purification Methods 0.000 description 53
239000000872 buffer Substances 0.000 description 45
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
238000004113 cell culture Methods 0.000 description 15
239000012228 culture supernatant Substances 0.000 description 15
150000003839 salts Chemical class 0.000 description 15
239000011780 sodium chloride Substances 0.000 description 15
238000005571 anion exchange chromatography Methods 0.000 description 12
230000000694 effects Effects 0.000 description 12
102100022641 Coagulation factor IX Human genes 0.000 description 11
108010076282 Factor IX Proteins 0.000 description 11
230000027455 binding Effects 0.000 description 11
229960004222 factor ix Drugs 0.000 description 11
239000000463 material Substances 0.000 description 11
238000001042 affinity chromatography Methods 0.000 description 10
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 9
229960002897 heparin Drugs 0.000 description 9
229920000669 heparin Polymers 0.000 description 9
239000006143 cell culture medium Substances 0.000 description 8
229920002684 Sepharose Polymers 0.000 description 7
150000001768 cations Chemical class 0.000 description 7
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
238000001179 sorption measurement Methods 0.000 description 7
108010094028 Prothrombin Proteins 0.000 description 6
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
238000002955 isolation Methods 0.000 description 6
210000004027 cell Anatomy 0.000 description 5
230000015271 coagulation Effects 0.000 description 5
238000005345 coagulation Methods 0.000 description 5
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 4
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
238000001502 gel electrophoresis Methods 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
238000005406 washing Methods 0.000 description 4
238000009010 Bradford assay Methods 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229960003531 phenolsulfonphthalein Drugs 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
OYCLSQDXZMROJK-UHFFFAOYSA-N 2-bromo-4-[3-(3-bromo-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenol Chemical compound C1=C(Br)C(O)=CC=C1C1(C=2C=C(Br)C(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 OYCLSQDXZMROJK-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
102100023804 Coagulation factor VII Human genes 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108010023321 Factor VII Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
239000012564 Q sepharose fast flow resin Substances 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
229940012413 factor vii Drugs 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
-1 amino anion Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
229940006612 barium citrate Drugs 0.000 description 1
PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
229940019700 blood coagulation factors Drugs 0.000 description 1
102000021115 calcium ion binding proteins Human genes 0.000 description 1
108091011132 calcium ion binding proteins Proteins 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
201000003740 cowpox Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Treatment Of Liquids With Adsorbents In General (AREA)

NO19950733A 1994-02-28 1995-02-27 Fremgangsmate for separasjon av et vitamin K-avhengig protein fra ikke-vitamin K-avhengige, medfolgende proteiner fra en proteinholdig losning NO322372B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4406515A DE4406515C1 (de)	1994-02-28	1994-02-28	Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine

Publications (3)

Publication Number	Publication Date
NO950733D0 NO950733D0 (no)	1995-02-27
NO950733L NO950733L (no)	1995-08-29
NO322372B1 true NO322372B1 (no)	2006-09-25

Family

ID=6511421

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19950733A NO322372B1 (no)	1994-02-28	1995-02-27	Fremgangsmate for separasjon av et vitamin K-avhengig protein fra ikke-vitamin K-avhengige, medfolgende proteiner fra en proteinholdig losning

Country Status (13)

Country	Link
US (1)	US5633350A (fr)
EP (1)	EP0669342B1 (fr)
JP (1)	JPH07258286A (fr)
AT (1)	ATE205218T1 (fr)
CA (1)	CA2143510C (fr)
CZ (1)	CZ290471B6 (fr)
DE (1)	DE4406515C1 (fr)
DK (1)	DK0669342T3 (fr)
ES (1)	ES2161790T3 (fr)
FI (1)	FI116526B (fr)
HU (1)	HU219828B (fr)
NO (1)	NO322372B1 (fr)
SK (1)	SK22695A3 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69926226T2 (de) *	1998-04-15	2006-05-24	Novo Nordisk A/S	Neues verfahren zur trennung von proteinen unter verwendung eines ca++ enthaltenden elutionsmittels
DE60138111D1 (de) *	2000-07-21	2009-05-07	Chemo Sero Therapeut Res Inst	Verfahren zur reinigung eines kalziumionen-bindenden proteins
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
JP2008525381A (ja) *	2004-12-23	2008-07-17	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	関心のあるビタミンｋ依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少
US20090047723A1 (en) *	2005-01-14	2009-02-19	Bayer Healthcare Llc	Method for purification of factor vii
RU2440810C2 (ru) *	2005-04-28	2012-01-27	Ново Нордиск Хелс Кеа Аг	Закрытый контейнер, содержащий активированный полипептид фактора vii, способы его получения и набор и способ применения набора
US7375084B2 (en)	2006-03-07	2008-05-20	Baxter International Inc.	Highly phosphorylated and sulfated recombinant factor IX
DK2125866T3 (da) *	2007-02-28	2013-07-29	Baxter Int	Fremgangsmåde til rensning af rekombinant blodkoagulationsfaktor IX, som er beriget med sulfaterede og/eller phosphorylerede molekyler
EP2526115B1 (fr) *	2010-01-18	2018-08-01	Novo Nordisk Health Care AG	Purification des facteurs de coagulation sanguine
JP5883849B2 (ja)	2010-04-29	2016-03-15	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	陰イオン交換樹脂を用いる二価カチオン結合タンパク質の精製方法
WO2012104339A1 (fr)	2011-02-01	2012-08-09	Novo Nordisk A/S	Purification d'insuline
EP2748180B1 (fr)	2011-10-14	2018-08-15	Baxalta GmbH	Purification de protéines par chromatographie par echange d'anions
LT2748179T (lt) *	2011-10-14	2022-04-11	Takeda Pharmaceutical Company Limited	Baltymų gryninimas anijonų mainų chromatografija
TR201808584T4 (tr) *	2013-03-15	2018-07-23	Baxalta GmbH	Anyon değişimi kromotografisi aracılığıyla k vitaminine bağlı proteinler için saflaştırma yöntemi.
JP7606185B2 (ja) *	2020-09-03	2024-12-25	日機装株式会社	フェノールレッド吸着剤およびフェノールレッドの除去方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3101752A1 (de) *	1981-01-21	1982-08-26	Behringwerke Ag, 3550 Marburg	"verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
EP0317376B2 (fr) *	1987-10-23	1996-04-03	Centre Regional De Transfusion Sanguine De Lille	Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
US4981952A (en) *	1988-10-04	1991-01-01	Eli Lilly And Company	Method for the purification of vitamin K-dependent proteins
AT395596B (de) *	1991-06-20	1993-01-25	Immuno Ag	Verfahren zur herstellung von aktiviertem protein c

1994
- 1994-02-28 DE DE4406515A patent/DE4406515C1/de not_active Expired - Lifetime
1995
- 1995-02-20 SK SK226-95A patent/SK22695A3/sk unknown
- 1995-02-22 ES ES95102504T patent/ES2161790T3/es not_active Expired - Lifetime
- 1995-02-22 DK DK95102504T patent/DK0669342T3/da active
- 1995-02-22 AT AT95102504T patent/ATE205218T1/de active
- 1995-02-22 EP EP95102504A patent/EP0669342B1/fr not_active Expired - Lifetime
- 1995-02-27 CA CA002143510A patent/CA2143510C/fr not_active Expired - Fee Related
- 1995-02-27 HU HU9500594A patent/HU219828B/hu not_active IP Right Cessation
- 1995-02-27 NO NO19950733A patent/NO322372B1/no not_active IP Right Cessation
- 1995-02-27 US US08/394,508 patent/US5633350A/en not_active Expired - Lifetime
- 1995-02-27 FI FI950888A patent/FI116526B/fi not_active IP Right Cessation
- 1995-02-28 CZ CZ1995539A patent/CZ290471B6/cs not_active IP Right Cessation
- 1995-02-28 JP JP7064823A patent/JPH07258286A/ja active Pending

Also Published As

Publication number	Publication date
CZ290471B6 (cs)	2002-07-17
EP0669342A2 (fr)	1995-08-30
CA2143510C (fr)	1999-12-21
SK22695A3 (en)	1995-09-13
FI950888A0 (fi)	1995-02-27
FI116526B (fi)	2005-12-15
CA2143510A1 (fr)	1995-08-29
EP0669342B1 (fr)	2001-09-05
HU219828B (hu)	2001-08-28
US5633350A (en)	1997-05-27
NO950733L (no)	1995-08-29
HU9500594D0 (en)	1995-04-28
HUT72844A (en)	1996-05-28
ATE205218T1 (de)	2001-09-15
CZ53995A3 (en)	1995-09-13
DK0669342T3 (da)	2001-11-12
JPH07258286A (ja)	1995-10-09
DE4406515C1 (de)	1995-10-19
ES2161790T3 (es)	2001-12-16
NO950733D0 (no)	1995-02-27
EP0669342A3 (fr)	1997-04-16
FI950888L (fi)	1995-08-29

Legal Events

Date	Code	Title	Description
2014-09-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
DK176090B1 (da)	2006-05-22	Fremgangsmåde til oprensning af proteiner
US6627737B1 (en)	2003-09-30	Factor IX purification methods
US5633350A (en)	1997-05-27	Method for the isolation and purification of vitamin K-dependent proteins
EP0317376B1 (fr)	1993-01-13	Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
Sternberg	1971	Crystalline milk-clotting protease from Mucor miehei and some of its properties
JP6820232B2 (ja)	2021-01-27	アニオン交換クロマトグラフィーによるタンパク質の精製
CA1078732A (fr)	1980-06-03	Procede de preparation d'enzymes thrombinoides a partir de venin de serpent
JPH0386900A (ja)	1991-04-11	新規なトロンビン結合性物質及びその製法
NO178882B (no)	1996-03-18	Fremgangsmåte for separasjon av vitamin K-avhengige blodkoagulerende faktorer
US5831025A (en)	1998-11-03	Human activated protein C and process for preparing same
Børresen et al.	1989	Purification and characterisation of tyrosine decar☐ ylase and aromatic-l-amino-acid decar☐ ylase
Grant et al.	1976	Rat liver prothrombin precursors: purification of a second, more basic form
RU2186849C2 (ru)	2002-08-10	Способ очистки тромбиноподобной протеазы из змеиного яда
Brosstad	1977	Purification, characterization and insolubilization of bovine thrombin
Vician et al.	1976	Purification of human blood clotting factor X by blue dextran agarose affinity chromatography
Belyauskaite et al.	1980	Purification and some properties of the extracellular acid proteases from Mucor renninus
Lykins et al.	1977	Dissociation and reconstitution of human ferroxidase II
SU1175965A1 (ru)	1985-08-30	Способ выделени урокиназы из биологических источников
JPH04365481A (ja)	1992-12-17	トロンビンの製造法
Mazitsos et al.	2004	Designed chimaeric galactosyl–mimodye ligands for the purification of Pseudomonas fluorescens β-galactose dehydrogenase
JP2016512215A (ja)	2016-04-25	陰イオン交換クロマトグラフィーによるビタミンｋ依存性タンパク質の精製方法
JPS6336781A (ja)	1988-02-17	高純度組織性プラスミノ−ゲン活性化因子の製法
JP2000166545A (ja)	2000-06-20	胆汁酸活性化リパーゼ
JPS61246131A (ja)	1986-11-01	新しいタイプのプラスミノ−ゲン活性化因子及びその調製方法